Scientist, Analytical Development at Acadia Pharmaceuticals

Minneapolis, Minnesota, United States

Acadia Pharmaceuticals Logo
Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biopharmaceutical, MicrobiomeIndustries

Requirements

  • PhD (2+ years of experience), Master’s Degree (7+ years of experience) or bachelor’s degree (10+ years of experience) in biochemistry, molecular biology, or a related field
  • Experience with molecular biology techniques (DNA sample preparation, qPCR, sequencing, mass spec, flow cytometry, etc) is required
  • Experience in assay development/validation, microbiome, and cGMP is required
  • Ability and desire to work independently as well as in a collaborative team-environment
  • Utilization of a continuous learning mindset to drive new technologies and solutions
  • Self-motivated individual able to drive projects forward with accountability for required timelines
  • Excellent oral and written communication skills
  • Organized and detail oriented
  • Role is located in Roseville, MN

Responsibilities

  • Leading internal projects for the development, validation, and implementation of molecular-biology-based analytical test methods for characterization and monitoring of the next generation of microbiome therapy products (qPCR, NGS, LC/GC-MS, Flow Cytometry, others)
  • Actively leverage knowledge and literature resources to ensure regulatory requirements (cGMP) are satisfied during assay development
  • Execution of DNA extraction, sequencing library preparation, sequencing method execution, and data analysis
  • Collaborate closely with other functions to enable effective and successful project execution
  • Optimization and troubleshooting of assay designs
  • Leading external contract research organization projects
  • Actively engage in cross-functional collaborations with peers to overcome challenges
  • Organize, communicate, and present complex data to key stakeholders and senior management
  • Compile documentation (protocols, test methods, reports) to facilitate the transfer of analytical methods to Quality Control
  • Lab equipment maintenance, cleanliness and SOP updates

Skills

qPCR
NGS
LC-MS
GC-MS
Flow Cytometry
DNA extraction
sequencing library preparation
data analysis
cGMP
assay development
molecular biology

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters
1993Year Founded
$813.4MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Holidays
Paid Sick Leave
Paid Parental Leave
Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.
Potential clinical trial delays could affect drug approval timelines.
Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.
The company has a strong R&D foundation, developing innovative small molecule drugs.
Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.
Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.
The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI